Mark Chao is a physician-scientist and biotech entrepreneur with over 20 years of experience in oncology research.  He was a co-founder and SVP of clinical development at Forty Seven, Inc., an immuno-oncology company developing macrophage-directed therapeutics which was acquired by Gilead Sciences for $4.9B in 2020.  As one of the scientific pioneers discovering CD47, an anti-phagocytic signal, as a therapeutic target in oncology, Mark helped lead research and oversaw clinical development of magrolimab, a first-in-class CD47 targeting antibody across multiple cancers from early to late stage development.  He is currently VP in oncology clinical research at Gilead Sciences, where he is the global development lead for magrolimab.  He received his PhD in cancer biology in the lab of Dr. Irving Weissman, MD and conducted his internal medicine and hematology training at Stanford University.  He serves on the board of directors for Hepatx Corporation, the Silicon Valley chapter of the Leukemia Lymphoma Society and on the scientific advisory board of Iconovir Bio and TigaTx.

Dr. Michalski is a physician executive working at the interface of technology and clinical medicine. He was previously the founder and executive director of the Massachusetts General Brigham Center for Clinical Data Science (CCDS) where he oversaw a staff of approximately 40, including data scientists, software engineers, data engineers, researchers, trainees, and clinical experts. Regarded as an emerging leader at the center of the application AI in clinical medicine, the CCDS was formulated as an early-stage technology company focused on developing and translating AI technology for clinical applications, operations, and population health. Previous to this role, Dr. Michalski helped create and grow two medical device/diagnostic companies: Butterfly Network (a novel ultrasound-based technology which has recently gone public) and Hyperfine Research (which developed the world’s first portable MRI), where he served in leadership roles at both organizations (as president and chief medical officer). He has conducted research focused on machine learning, medical 3-D printing, molecular diagnostics and other areas, and has published in JAMA, PLOS, and PNAS. Previous to these roles, Dr. Michalski worked with technology, healthcare, and strategy groups at Genentech and Google in various roles. He completed his clinical training in diagnostic radiology as a Holman fellow at Yale, and was a med scholars researcher at Stanford.